Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

History

Appeal

: Final scrutiny letter (PDF 187 KB)

Published:

16 August 2011

Background information

TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): review decision - August 2015 information
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - RPP decision paper - August 2015 (PDF 69 KB)

Published:

13 August 2015
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): review proposal - June 2015 information
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix A - matrix of stakeholders (PDF 98 KB)

Published:

29 June 2015
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appendix B - GE proposal paper - June 2015 (PDF 183 KB)

Published:

29 June 2015

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination 2

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination 2 information
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination document (PDF 281 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 254 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the ACD
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline (PDF 158 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche (PDF 422 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Breakthrough Breast Cancer (PDF 245 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Department of Health (PDF 46 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): HealthCare Improvement Scotland (PDF 11 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Nursing (PDF 57 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (joint NCRI, RCR, ACP) (PDF 234 KB)

Published:

27 April 2012
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Cameron information
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Cameron (PDF 148 KB)

Published:

27 April 2012

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation 2

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation document information

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appeal

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination information
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): final appraisal determination document (PDF 266 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 248 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the ACD
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline comments on the ACD (PDF 78 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): GlaxoSmithKline comments on executable model (PDF 66 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche comments on the ACD (PDF 259 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Roche comments on the AG model (PDF 81 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Nursing (PDF 60 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): NHS Portsmouth (PDF 93 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Department of Health (PDF 4.3 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Commissioning Support Appraisal Service (CSAS) (PDF 138 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Quality Improvement Scotland (QIS) (PDF 62 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Pfizer (PDF 71 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Royal College of Physicians (NCRI/RCP/RCR/ACP/JCCO) (PDF 85 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): comments on the ACD received from the public through the NICE website (PDF 216 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): responses to comments on the economic model by the Assessment Group (PDF 100 KB)

Published:

01 July 2011
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): addendum to assessment report (PDF 477 KB)

Published:

01 July 2011

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation document information
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): evaluation report
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): appraisal consultation overview (PDF 288 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): assessment report (PDF 2.05 MB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): assessment report erratum (PDF 349 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Glaxo Smith Kline (PDF 272 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Roche (PDF 80 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Royal College of Physicians (PDF 42 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Department of Health (PDF 63 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - Welsh Assembly Government (PDF 45 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): consultee and commentator comments on the assessment report - NHS - Quality Improvement Scotland (PDF 88 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): non-manufacturer submission
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): joint submission from Breast Cancer Care (PDF 107 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from the Royal College of Nursing (PDF 45 KB)

Published:

15 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from the Royal College of Physicians (PDF 193 KB)

Published:

15 December 2010
Manufacturer submissions (executive summary only)
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from Glaxo Smith Kline (PDF 84 KB)

Published:

14 December 2010
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): submission from Roche Products (PDF 83 KB)

Published:

15 December 2010

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Equality impact assessment - Guidance development

Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): Equality impact assessment - Guidance development (PDF 84 KB)

Published:

27 June 2012

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): assessment report for consultation

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): assessment report for consultation (PDF 2.06 MB)

Published:

07 October 2010

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final scope

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final scope (PDF 49 KB)

Published:

24 February 2010

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final matrix

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): final matrix (PDF 44 KB)

Published:

24 February 2010

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on draft scope

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on draft scope (PDF 48 KB)

Published:

24 February 2010

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on provisional matrix

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): response to consultee and commentator comments on provisional matrix (PDF 28 KB)

Published:

24 February 2010

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): draft scope for the appraisal

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): draft scope for the appraisal (PDF 20 KB)

Published:

17 November 2009

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): provisional matrix of consultees and commentators for the appraisal

Breast cancer (advanced) - lapatinib and trastuzumab (1st line): provisional matrix of consultees and commentators for the appraisal (PDF 25 KB)

Published:

17 November 2009